Related Experiment Video

Updated: Sep 8, 2025

Author Spotlight: Detection and Treatment of Helicobacter pylori Infection
06:40

Author Spotlight: Detection and Treatment of Helicobacter pylori Infection

Published on: July 28, 2023

3.7K

Helicobacter pylori infection is an infectious disease and the empiric therapy paradigm should be changed

Hong Li1, Tiankuo Yang1, Hong Tang1

  • 1West China Marshall Research Center for Infectious Diseases, Center of Infectious Diseases, Division of Infectious Diseases, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.

Precision Clinical Medicine
|June 13, 2022
PubMed

Insights

High antibiotic resistance in Helicobacter pylori necessitates a shift from standard treatment to precision medicine guided by antimicrobial susceptibility testing. Implementing stewardship programs is crucial for monitoring H. pylori resistance patterns.

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Gastroenterology

Background:

  • Helicobacter pylori (H. pylori) infection is a significant global health concern.
  • Alarmingly high rates of antibiotic resistance in H. pylori are compromising treatment efficacy.
  • Current empiric treatment strategies are becoming increasingly ineffective due to resistance.

Purpose of the Study:

  • To advocate for a paradigm shift in H. pylori treatment.
  • To emphasize the importance of antimicrobial susceptibility testing (AST)-guided therapy.
  • To promote the implementation of antimicrobial stewardship programs for H. pylori.

Main Methods:

  • Review of current H. pylori treatment guidelines and resistance data.
  • Analysis of the impact of antibiotic resistance on treatment outcomes.
  • Recommendations for integrating AST into clinical practice.

Main Results:

  • Empiric H. pylori treatment is failing due to widespread antibiotic resistance.
  • AST-guided precision treatment offers a more effective alternative.
  • Stewardship programs are vital for tracking and managing resistance.

Conclusions:

  • Gastroenterologists must transition from empiric to AST-guided H. pylori treatment.
  • Local, regional, and national antimicrobial stewardship programs are essential for monitoring H. pylori resistance.
  • Precision medicine approaches are critical for overcoming antibiotic resistance in H. pylori infections.
Keywords:
Helicobacter pyloriantimicrobial susceptibility testinginfectious disease

More Related Videos

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

492
Detection of Helicobacter pylori Infection and Antibiotic Resistance via Stool Quantitative Polymerase Chain Reaction Analysis04:56

Detection of Helicobacter pylori Infection and Antibiotic Resistance via Stool Quantitative Polymerase Chain Reaction Analysis

Published on: May 16, 2025

558

Related Concept Videos

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
546
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
144
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
568
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
193
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
525
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
462